The National Pharmaceutical Pricing Authority (NPPA) said however that the actual increase or decrease in prices after the rollout of new indirect tax regime is expected to be in be in the range of 2-3 per cent depending on states.
"In order to facilitate smooth implementation of GST for companies, we have worked out the provisional ceiling prices of 761 formulations," NPPA Chairman Bhupendra Singh told PTI.
He said the actual price increase or decrease in drug prices post GST would be nominal ranging between 2-3 per cent.
"These prices will be notified as formal revised ceiling prices immediately after GST notification," NPPA said.
As per the provisional list, ceiling price of various cancer drugs like Bortezomib, Docetaxel and Gemcitabine have been reduced.
Ceiling price of Bortezomib has been fixed at Rs 11,160.08 per pack, down from Rs 11,636.60 at present while that of a a pack of Docetaxel has been fixed at Rs 10,326.94 from Rs 10,767.88 currently.
Ceiling price of HIV combination drug of Tenofovir (300mg), Lamivudine (300mg) and Efavirenz (600mg) has been fixed at Rs 89.69 per tablet, down from Rs 93.52 per tablet earlier.
Price of one tablet of HIV treatment drug Darunavir has been fixed at Rs 151.4, down from Rs 157.93. Besides cost of one tablet of Lamivudine and Zidovudine combination has been reduced to Rs 18.20 from Rs 18.98 currently. Ceiling price of Eplilespy drug Levetiracetam has also been reduced.
Ceiling price of drug eluting stents will however remain unchanged at Rs 30,180. Ceiling price of Atorvastatin tablets, used to treat hypertension, has also been reduced.
Similarly, the ceiling prices of various antibiotics like Azithromycin, Ciprofloxacin, Clarithromycin, Ampicillin, Amoxicillin have also been lowered. Ibuprofen and Imatinib prices are also fixed at a lower slab.
Price of one tablet of Entecavir, used to treat Hepatitis B, has come down to Rs 69.44 from Rs 72.40.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
